A recent study reveals a significant surge in the use of medications for attention deficit/hyperactivity disorder (ADHD) in Ontario. Factors such as increased screen time and the availability of private assessments for this mental condition are believed to contribute to this rise.
The research, published in JAMA Network Open, analyzed prescriptions for stimulant drugs like Ritalin and Adderall dispensed in Ontario between 2015 and 2023. The data shows a 157% increase in new stimulant prescriptions by 2023 compared to 2015.
Throughout the study period, prescriptions for ADHD treatment steadily increased, with a notable acceleration in 2020, coinciding with the COVID-19 lockdowns. The annual growth rate of prescriptions spiked to 28% in 2020, up from 7% between 2015 and 2019.
Experts from ICES, North York General, and The Hospital for Sick Children suggest that the surge may be linked to various factors such as increased screen time, heightened awareness of ADHD symptoms, and the identification of previously undiagnosed individuals. However, concerns are raised about the appropriateness of these prescriptions, as some individuals might be misdiagnosed or overdiagnosed.
The study highlights a substantial increase in ADHD medication use among adult females, with growth rates of approximately 421% and 369% in the age groups of 25-44 and 18-24, respectively. Notably, by 2023, more females aged 25-44 had used stimulants in the past year than males.
Dr. Daniel Myran, the lead author, expressed worries about potential adverse effects of unnecessary medication and the possibility of overlooking other mental health conditions. The study also observed a notable rise in children starting ADHD medication, although not as pronounced as in adults.
During the pandemic, the emergence of virtual care clinics offering ADHD assessments online lowered diagnostic barriers but also raised concerns about misdiagnosis. Side effects of ADHD medication include appetite loss, sleep disturbances, anxiety, and potential long-term risks like increased blood pressure and heightened risks of stroke and heart attacks.
In British Columbia, a similar study conducted by Heather Palis revealed a comparable rise in ADHD diagnoses, particularly among females. The findings underscore the need for improved access to healthcare providers for proper diagnosis, treatment, and monitoring of patients for adverse effects.